Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study

Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study

Abstract: In the phase 3 POLARIX study, Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone) improved progression-free survival (PFS) vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously untreated diff...

Full description

Saved in:
Bibliographic Details
Main Authors: Bei Hu, Patrick M. Reagan, Laurie H. Sehn, Jeff P. Sharman, Mark Hertzberg, Huilai Zhang, Austin Kim, Charles Herbaux, Lysiane Molina, Dai Maruyama, Frank Stenner, Saibah Chohan, Rucha Kothari, Connie Lee Batlevi, Jamie Hirata, Deniz Sahin, Calvin Lee, Matthew Sugidono, Hervé Tilly
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925001697
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952925001697

Similar Items